SAN FRANCISCO and SUZHOU, China, Jan. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic,...
Hence then, the article about innovent receives nmpa breakthrough therapy designation for ibi343 anti cldn18 2 adc as monotherapy for advanced pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer )
Also on site :
- 15 Shows Like 'Widow's Bay' You Should Watch Next
- AI evaluation startup Braintrust confirms breach, tells every customer to rotate sensitive keys
- How the Fight Over Israel Is Playing Out Inside MAGA